- Predictive Oncology Develops Novel Stem Cell Expression System for the Production of Functional and Stable G-Protein Coupled Receptors (GPCRs)
- Predictive Oncology Launches Novel 3D Cell Technology to Accelerate Cancer Therapeutic Drug Discovery
- Predictive Oncology Announces CEO Raymond Vennare to Present at the BIO International Convention 2024
- Predictive Oncology Announces Positive Results from Ovarian Cancer Study with UPMC Magee-Womens Hospital to be Presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Predictive Oncology Reports First Quarter 2024 Financial Results and Provides Business Update
- Predictive Oncology to Report First Quarter 2024 Financial Results on Wednesday, May 15, 2024
- Predictive Oncology Announces Significant Progress with FluGen In the Development of First-of-Its-Kind Intranasal Flu Vaccine
- Predictive Oncology Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update
- Predictive Oncology to Participate in Upcoming Investor Conferences
More ▼
Key statistics
On Friday, Predictive Oncology Inc (POAI:NAQ) closed at 1.22, 8.93% above its 52-week low of 1.12, set on Apr 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.25 |
---|---|
High | 1.25 |
Low | 1.19 |
Bid | 1.20 |
Offer | 1.27 |
Previous close | 1.26 |
Average volume | 172.81k |
---|---|
Shares outstanding | 4.10m |
Free float | 3.96m |
P/E (TTM) | -- |
Market cap | 5.00m USD |
EPS (TTM) | -3.66 USD |
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
More ▼